News stories about Amicus Therapeutics (NASDAQ:FOLD) have trended somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Amicus Therapeutics earned a news impact score of 0.24 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.7314045068498 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:
- Amicus Therapeutics (FOLD) Upgraded to “Hold” at ValuEngine (americanbankingnews.com)
- Galafold Approved for Fabry Disease in Japan (pharmalive.com)
- Eye Catching Stock for Investors: Amicus Therapeutics, Inc. (FOLD) – MostVolatileStocks (press release) (mostvolatilestocks.com)
- Notable Stocks Under Consideration: Amicus Therapeutics, Inc., (NASDAQ: FOLD), Devon Energy Corporation, (NYSE … – Global Export Lines (press release) (globalexportlines.com)
- Zacks Investment Research Upgrades Amicus Therapeutics (FOLD) to “Hold” (americanbankingnews.com)
Several brokerages have recently commented on FOLD. Zacks Investment Research downgraded shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, December 19th. BidaskClub cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, February 13th. Robert W. Baird set a $20.00 target price on Amicus Therapeutics and gave the stock a “buy” rating in a report on Wednesday, February 7th. Finally, Cowen reiterated a “buy” rating and issued a $22.00 target price on shares of Amicus Therapeutics in a report on Wednesday, January 10th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $19.06.
Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.11). Amicus Therapeutics had a negative return on equity of 71.06% and a negative net margin of 769.03%. The firm had revenue of $14.73 million during the quarter, compared to the consensus estimate of $14.50 million. analysts predict that Amicus Therapeutics will post -1.26 earnings per share for the current year.
In related news, major shareholder Perceptive Advisors Llc acquired 335,827 shares of the company’s stock in a transaction on Monday, March 5th. The shares were acquired at an average cost of $13.56 per share, for a total transaction of $4,553,814.12. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, CFO William D. Baird III sold 10,000 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $14.72, for a total value of $147,200.00. Following the transaction, the chief financial officer now owns 105,121 shares in the company, valued at $1,547,381.12. The disclosure for this sale can be found here. Over the last quarter, insiders sold 142,289 shares of company stock worth $2,180,112. 3.40% of the stock is owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Amicus Therapeutics (FOLD) Share Price” was published by Ticker Report and is owned by of Ticker Report. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3303527/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-amicus-therapeutics-fold-share-price.html.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.